share_log

Annovis Announces New Publication in a Peer-Reviewed Journal

Annovis Announces New Publication in a Peer-Reviewed Journal

Annovis宣佈在同行評審期刊上發表新文章
Annovis Bio ·  05/21 12:00

Tue, 21 May 2024

2024 年 5 月 21 日,星期二

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.

賓夕法尼亞州馬爾文,2024年5月21日(GLOBE NEWSWIRE)——開發神經退行性疾病新療法的臨床階段藥物平台公司Annovis Bio, Inc.(紐約證券交易所代碼:ANVS)(“Annovis” 或 “公司”)宣佈發表一篇新文章,重點比較不同物種中Posiphen(或buntanetap)的藥代動力學特徵同行評審期刊 生物分子 作爲其中的一部分 特刊:澱粉樣蛋白在神經系統疾病中的作用

"This publication is a testament to many years of research at Annovis. While we have conducted numerous studies to advance our Posiphen pipeline, this is the first systematic and comprehensive comparison in multiple animal and human samples," says Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Consolidating all this data into one publication offers a more holistic view of Posiphen, enhancing our understanding of its mechanisms."

“這份出版物證明了Annovis多年的研究。儘管我們已經進行了大量研究以推進Posiphen產品線,但這是首次對多個動物和人類樣本進行系統和全面的比較。” Annovis創始人、總裁兼首席執行官Maria Maccecchini博士說。“將所有這些數據整合到一份出版物中,可以更全面地了解Posiphen,從而增進我們對其機制的理解。”

Summary: This article synthesizes findings from various preclinical and clinical studies on Posiphen's absorption and metabolism from mice, rats, dogs, and humans. The aim was to better understand the differences in the drug's pharmacokinetic behavior, identify which animal models most closely mimic human responses, and explore the potential clinical implications of these variations.

摘要:本文綜合了關於小鼠、大鼠、狗和人類對Posiphen吸收和代謝的各種臨床前和臨床研究的結果。目的是更好地了解藥物藥代動力學行爲的差異,確定哪些動物模型最能模仿人類反應,並探索這些變異的潛在臨床影響。

Key highlights:

主要亮點:

  • Posiphen quickly reaches peak concentration in plasma, followed by high absorption in the brain and cerebrospinal fluid (CSF).
  • Posiphen metabolizes into two primary metabolites: N1-norposiphen and N8-norposiphen.
  • Both Posiphen and its metabolites exhibit rapid clearance in animal models and human subjects; however, in the CSF or the brain, the drug stays longer.
  • Posiphen's absorption, distribution, metabolism, and excretion are similar in healthy volunteers and patients with Alzheimer's and Parkinson's diseases.
  • Posiphen在血漿中迅速達到峯值濃度,隨後在大腦和腦脊液(CSF)中吸收率很高。
  • Posiphen 代謝成兩種主要代謝物:n1-norposiphen 和 n8-norposiphen。
  • Posiphen及其代謝物在動物模型和人體受試者中均表現出快速清除率;但是,在腦脊液或大腦中,藥物的停留時間更長。
  • Posiphen在健康志願者和阿爾茨海默氏症和帕金森氏病患者中的吸收、分佈、代謝和排泄相似。

The article can be found on the journal's website via the link.

該文章可通過以下方式在該期刊的網站上找到 鏈接

About Annovis Bio, Inc.

關於 Annovis Bio, Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), and other chronic neurodegenerative diseases. It is believed to be the only company developing a drug for both AD and PD designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the company's goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and X (formerly known as Twitter).

Annovis Bio, Inc. 總部位於賓夕法尼亞州馬爾文,是一家臨床階段的藥物平台公司,致力於治療神經變性,例如阿爾茨海默氏病(AD)、帕金森氏病(PD)和其他慢性神經退行性疾病。據信它是唯一一家同時開發AD和PD藥物的公司,該藥物旨在抑制一種以上的神經毒性蛋白質,以恢復軸突和突觸活性。通過改善大腦功能,該公司的目標是治療與AD相關的記憶力減退和癡呆以及與PD相關的身體和大腦功能障礙。有關Annovis Bio的更多信息,請訪問該公司的網站 www.annovisbio.co 然後關注我們 領英X(以前稱爲 Twitter)。

Forward-Looking Statements

前瞻性陳述

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

本新聞稿包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的 “前瞻性” 陳述。除歷史事實陳述以外的所有陳述均可被視爲前瞻性陳述。該公司建議謹慎對待前瞻性陳述。前瞻性陳述包括但不限於公司與臨床試驗相關的計劃。這些陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際結果與前瞻性陳述所暗示的結果存在重大差異,包括患者入組、Buntanetap的有效性以及公司評估buntanetap療效、安全性和耐受性的臨床試驗的時機、有效性和預期結果。另請參閱公司向美國證券交易委員會提交的定期文件中列出的其他風險因素,包括但不限於公司向美國證券交易委員會提交的10-K表年度報告和10-Q表季度報告中 “風險因素” 部分中列出的風險和不確定性。本新聞稿中的所有前瞻性陳述均基於公司截至本申報之日獲得的信息。除非適用法律要求,否則公司明確表示不承擔任何更新或修改其前瞻性陳述的義務,無論是由於新信息、未來事件還是其他原因。

Investor Contact:
Maria Maccecchini, Ph.D.
maccecchini@annovisbio.com

投資者聯繫人:
瑪麗亞·馬切基尼博士
maccecchini@annovisbio.com

Primary Logo

Source: Annovis Bio Inc.

資料來源:Annovis Bio Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論